MX381829B - Composiciones anticancerígenas. - Google Patents
Composiciones anticancerígenas.Info
- Publication number
- MX381829B MX381829B MX2017007206A MX2017007206A MX381829B MX 381829 B MX381829 B MX 381829B MX 2017007206 A MX2017007206 A MX 2017007206A MX 2017007206 A MX2017007206 A MX 2017007206A MX 381829 B MX381829 B MX 381829B
- Authority
- MX
- Mexico
- Prior art keywords
- arn
- prostate cancer
- hpmcas
- meth
- poly
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención se refiere a formulaciones farmacéuticas de ARN-509, que pueden administrarse a un mamífero, en particular a un humano, que sufre de una enfermedad o trastorno relacionado con el receptor andrógeno (AR), en particular cáncer, más en particular cáncer de próstata, incluyendo pero no limitado a cáncer de próstata resistente a la castración, cáncer de próstata resistente a la castración metastático, cáncer de próstata resistente a la castración metastático que no ha tenido quimioterapia, cáncer de próstata sensitivo a hormonas reincidido bioquímicamente o cáncer de próstata resistente a la castración no metastático de alto riesgo; en un aspecto, estas formulaciones comprenden una dispersión sólida de ARN-509, un copolímero de poli(met)acrilato y HPMCAS; en un aspecto, la dispersión sólida de ARN-509, un copolímero de poli(met)acrilato y HPMCAS se puede obtener, en particular se obtiene, mediante extrusión por fusión de una mezcla que comprende ARN-509, un copolímero de poli(met)acrilato y HPMCAS y opcionalmente moler después dicha mezcla extrudida por fusión; en un aspecto, la dispersión sólida de ARN-509, un copolímero de poli(met)acrilato y HPMCAS se puede obtener, en particular se obtiene, mediante secado por aspersión de una mezcla que contiene ARN-509, un copolímero de poli(met)acrilato y HPMCAS en un solvente adecuado.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14196605 | 2014-12-05 | ||
| PCT/US2015/063671 WO2016090105A1 (en) | 2014-12-05 | 2015-12-03 | Anticancer compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017007206A MX2017007206A (es) | 2018-01-30 |
| MX381829B true MX381829B (es) | 2025-03-13 |
Family
ID=52006907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017007206A MX381829B (es) | 2014-12-05 | 2015-12-03 | Composiciones anticancerígenas. |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US10285948B2 (es) |
| EP (2) | EP3925598B1 (es) |
| JP (1) | JP6830892B2 (es) |
| KR (1) | KR102387089B1 (es) |
| CN (1) | CN106999432A (es) |
| AR (1) | AR102925A1 (es) |
| AU (1) | AU2015358497B2 (es) |
| CA (1) | CA2969675C (es) |
| CL (1) | CL2017001373A1 (es) |
| CO (1) | CO2017005574A2 (es) |
| CR (1) | CR20170218A (es) |
| CY (1) | CY1124504T1 (es) |
| DK (1) | DK3226843T3 (es) |
| EA (1) | EA201791251A1 (es) |
| ES (2) | ES2883187T3 (es) |
| HR (1) | HRP20211140T1 (es) |
| HU (1) | HUE054935T2 (es) |
| IL (1) | IL252325A0 (es) |
| LT (1) | LT3226843T (es) |
| MA (1) | MA41111B1 (es) |
| MD (1) | MD3226843T2 (es) |
| MX (1) | MX381829B (es) |
| MY (1) | MY192931A (es) |
| NI (1) | NI201700068A (es) |
| PH (1) | PH12017500979A1 (es) |
| PL (1) | PL3226843T3 (es) |
| PT (1) | PT3226843T (es) |
| RS (1) | RS62421B1 (es) |
| SG (1) | SG11201704386VA (es) |
| SI (1) | SI3226843T1 (es) |
| SM (1) | SMT202100454T1 (es) |
| TW (1) | TWI709403B (es) |
| UA (1) | UA123538C2 (es) |
| WO (1) | WO2016090105A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA117663C2 (uk) | 2012-09-26 | 2018-09-10 | Арагон Фармасьютікалз, Інк. | Антиандроген для лікування неметастатичного кастраційно-резистентного раку передміхурової залози |
| MA41107B1 (fr) | 2014-12-05 | 2025-01-31 | Aragon Pharmaceuticals, Inc. | Compositions anti-cancéreuses |
| LT3226843T (lt) | 2014-12-05 | 2021-08-10 | Aragon Pharmaceuticals, Inc. | Priešvėžinės kompozicijos |
| US10702508B2 (en) | 2017-10-16 | 2020-07-07 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer |
| WO2020144650A1 (en) | 2019-01-10 | 2020-07-16 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of prostate cancer |
| PH12021551657A1 (en) | 2019-01-30 | 2022-05-02 | Aragon Pharmaceuticals Inc | Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer |
| CN113711316A (zh) | 2019-01-30 | 2021-11-26 | 詹森药业有限公司 | 基于分子亚型治疗前列腺癌的方法 |
| WO2020239478A1 (en) | 2019-05-28 | 2020-12-03 | Pharma Mar, S.A. | Trabectedin for treating sarcomas based on genomic markers |
| JP2023500935A (ja) | 2019-11-04 | 2023-01-11 | アラゴン ファーマシューティカルズ，インコーポレイテッド | 重度の肝障害を有する対象における非転移性去勢抵抗性前立腺癌の治療のためのアンドロゲン受容体阻害剤 |
| WO2021245285A1 (en) | 2020-06-05 | 2021-12-09 | Janssen Pharmaceutica Nv | Methods of treating prostate cancer based on molecular subtypes |
| TW202228794A (zh) | 2020-09-04 | 2022-08-01 | 美商艾瑞岡醫藥公司 | 用於治療前列腺癌之方法 |
| WO2022195407A1 (en) | 2021-03-19 | 2022-09-22 | Aragon Pharmaceuticals, Inc. | Methods for treating prostate cancer |
| WO2023152611A1 (en) | 2022-02-11 | 2023-08-17 | Aragon Pharmaceuticals, Inc. | Apalutamide and relugolix for the treatment of prostate cancer |
| WO2023209555A1 (en) | 2022-04-26 | 2023-11-02 | Aragon Pharmaceuticals, Inc. | Approved drug products and methods for treating prostate cancer |
| AU2024236119A1 (en) | 2023-03-16 | 2025-09-25 | Bayer Consumer Care Ag | Androgen receptor antagonists for the treatment of patients with biochemical recurrence of hormone sensitive prostate cancer |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993020097A1 (en) | 1992-03-31 | 1993-10-14 | British Technology Group Ltd. | 17-substituted steroids useful in cancer treatment |
| PT901786E (pt) | 1997-08-11 | 2007-08-07 | Pfizer Prod Inc | Disperções farmacêuticas sólidas com biodisponibilidade melhorada |
| CA2400845A1 (en) | 2000-02-21 | 2001-08-23 | Takeda Chemical Industries, Ltd. | Sustained-release preparation of physiologically active compound slightly soluble in water and production process and use of the same |
| KR20030077042A (ko) | 2001-02-27 | 2003-09-29 | 아스트라제네카 아베 | 비칼루타마이드를 포함하는 약학 제제 |
| WO2002080902A1 (en) | 2001-04-02 | 2002-10-17 | Astrazeneca Ab | Solid pharmaceutical composition comprising 4 -cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono- m toluidide and pvp |
| ATE480226T1 (de) | 2001-06-22 | 2010-09-15 | Bend Res Inc | Pharmazeutische zusammensetzung enthaltend schwer lösliche und säureempfindliche arzneistoffe und neutralisierte anionische polymere |
| SE0103424D0 (sv) | 2001-10-15 | 2001-10-15 | Astrazeneca Ab | Pharmaceutical formulation |
| PL371593A1 (en) | 2002-02-01 | 2005-06-27 | Pfizer Products Inc. | Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles |
| WO2003077827A1 (en) | 2002-03-19 | 2003-09-25 | Nippon Shinyaku Co., Ltd. | Process for producing drug solid dispersion |
| WO2005055987A1 (en) | 2003-12-15 | 2005-06-23 | Council Of Scientific & Industrial Research | TASTE MASKED PHARMACEUTICAL COMPOSITIONS COMPRISING BITTER DRUG AND pH SENSITIVE POLYMER |
| LT2656841T (lt) | 2006-03-27 | 2016-09-26 | The Regents Of The University Of California | Androgeno receptoriaus moduliatorius, skirtas prostatos vėžio ir su androgeno receptoriumi susijusių ligų gydymui |
| EA022924B1 (ru) * | 2009-04-03 | 2016-03-31 | Ф.Хоффманн-Ля Рош Аг | ТВЁРДАЯ ФОРМА {3-[5-(4-ХЛОРФЕНИЛ)-1Н-ПИРРОЛО[2,3-b]ПИРИДИН-3-КАРБОНИЛ]-2,4-ДИФТОРФЕНИЛ}АМИДА ПРОПАН-1-СУЛЬФОНОВОЙ КИСЛОТЫ И ЕЁ ПРИМЕНЕНИЕ |
| AU2011218173C1 (en) | 2010-02-16 | 2015-04-16 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulators and uses thereof |
| CN102525876B (zh) * | 2010-12-15 | 2014-03-12 | 西安力邦医药科技有限责任公司 | 阿司匹林固体分散体、其制备方法、药物组合物和用途 |
| EP2721003B1 (en) | 2011-06-15 | 2018-01-03 | The United States of America, as Represented by The Secretary, Department of Health and Human Services | Nuclear receptor modulators and their use for the treatment and prevention of cancer |
| US20150037407A1 (en) | 2012-03-21 | 2015-02-05 | Emphascience, Inc. | Method to improve the safety of handling of high potency drugs in solid dosage forms without changing their efficacy |
| WO2013152342A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Anti-cancer mtor inhibitor and anti-androgen combination |
| US9481663B2 (en) * | 2012-06-07 | 2016-11-01 | Aragon Pharmaceuticals, Inc. | Crystalline forms of an androgen receptor modulator |
| US10668156B2 (en) | 2012-06-22 | 2020-06-02 | Basf Se | Active-ingredient-containing solid dispersions based on diethylaminoethyl methacrylate copolymers |
| WO2014031422A1 (en) | 2012-08-24 | 2014-02-27 | Dow Global Technologies Llc | Novel hydroxyalkyl methyl cellulose acetate succinates |
| US9977033B2 (en) | 2012-09-11 | 2018-05-22 | The Board Of Regents Of The University Of Texas System | Methods for assessing cancer recurrence |
| ES2892029T3 (es) | 2012-09-11 | 2022-02-01 | Medivation Prostate Therapeutics Llc | Formulaciones de enzalutamida |
| UA117663C2 (uk) * | 2012-09-26 | 2018-09-10 | Арагон Фармасьютікалз, Інк. | Антиандроген для лікування неметастатичного кастраційно-резистентного раку передміхурової залози |
| JOP20200097A1 (ar) | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
| BR112015015758B1 (pt) | 2013-01-22 | 2022-01-04 | F. Hoffmann-La Roche Ag | Dispersão sólida, formulação sólida de dose unitária, preparação farmacêutica e uso de uma dispersão sólida |
| KR20160023641A (ko) | 2013-03-15 | 2016-03-03 | 아이슈티카 인코포레이티드 | 아비라테론 아세테이트 제제 |
| WO2014167428A2 (en) | 2013-04-10 | 2014-10-16 | Shilpa Medicare Limited | Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide |
| JP2016528252A (ja) | 2013-08-12 | 2016-09-15 | トーカイ ファーマシューティカルズ， インコーポレイテッド | アンドロゲン標的治療を使用する新生物障害の処置のためのバイオマーカー |
| WO2015116696A1 (en) * | 2014-01-28 | 2015-08-06 | Massachusetts Institute Of Technology | Combination therapies and methods of use thereof for treating cancer |
| EP3102183A1 (en) * | 2014-02-05 | 2016-12-14 | LEK Pharmaceuticals d.d. | Solid pharmaceutical compositions of androgen receptor antagonists |
| EA201992609A1 (ru) | 2014-02-06 | 2020-03-04 | Ф.Хоффманн-Ля Рош Аг | Слитые белки, содержащие интерлейкин-2, и их применения |
| TWI803187B (zh) | 2014-08-08 | 2023-05-21 | 日商中外製藥股份有限公司 | 包含４環性化合物的非晶質體之固體分散體及製劑 |
| PT3226842T (pt) | 2014-12-05 | 2020-12-23 | Aragon Pharmaceuticals Inc | Composições anticancerígenas |
| LT3226843T (lt) | 2014-12-05 | 2021-08-10 | Aragon Pharmaceuticals, Inc. | Priešvėžinės kompozicijos |
| MA41107B1 (fr) | 2014-12-05 | 2025-01-31 | Aragon Pharmaceuticals, Inc. | Compositions anti-cancéreuses |
| AR108489A1 (es) * | 2016-06-03 | 2018-08-29 | Aragon Pharmaceuticals Inc | Composiciones antineoplásicas |
-
2015
- 2015-12-03 LT LTEP15820351.3T patent/LT3226843T/lt unknown
- 2015-12-03 SG SG11201704386VA patent/SG11201704386VA/en unknown
- 2015-12-03 MD MDE20170154T patent/MD3226843T2/ro not_active IP Right Cessation
- 2015-12-03 ES ES15820351T patent/ES2883187T3/es active Active
- 2015-12-03 EP EP21175525.1A patent/EP3925598B1/en active Active
- 2015-12-03 MA MA41111A patent/MA41111B1/fr unknown
- 2015-12-03 CN CN201580066235.3A patent/CN106999432A/zh active Pending
- 2015-12-03 PT PT158203513T patent/PT3226843T/pt unknown
- 2015-12-03 RS RS20211035A patent/RS62421B1/sr unknown
- 2015-12-03 KR KR1020177018243A patent/KR102387089B1/ko active Active
- 2015-12-03 JP JP2017529774A patent/JP6830892B2/ja active Active
- 2015-12-03 EA EA201791251A patent/EA201791251A1/ru unknown
- 2015-12-03 PL PL15820351T patent/PL3226843T3/pl unknown
- 2015-12-03 HR HRP20211140TT patent/HRP20211140T1/hr unknown
- 2015-12-03 ES ES21175525T patent/ES3019912T3/es active Active
- 2015-12-03 UA UAA201707015A patent/UA123538C2/uk unknown
- 2015-12-03 CR CR20170218A patent/CR20170218A/es unknown
- 2015-12-03 SM SM20210454T patent/SMT202100454T1/it unknown
- 2015-12-03 HU HUE15820351A patent/HUE054935T2/hu unknown
- 2015-12-03 WO PCT/US2015/063671 patent/WO2016090105A1/en not_active Ceased
- 2015-12-03 SI SI201531686T patent/SI3226843T1/sl unknown
- 2015-12-03 DK DK15820351.3T patent/DK3226843T3/da active
- 2015-12-03 MX MX2017007206A patent/MX381829B/es unknown
- 2015-12-03 EP EP15820351.3A patent/EP3226843B1/en active Active
- 2015-12-03 US US15/533,229 patent/US10285948B2/en active Active
- 2015-12-03 AU AU2015358497A patent/AU2015358497B2/en active Active
- 2015-12-03 MY MYPI2017701986A patent/MY192931A/en unknown
- 2015-12-03 TW TW104140459A patent/TWI709403B/zh not_active IP Right Cessation
- 2015-12-03 CA CA2969675A patent/CA2969675C/en active Active
- 2015-12-04 AR ARP150103981A patent/AR102925A1/es unknown
-
2017
- 2017-05-16 IL IL252325A patent/IL252325A0/en unknown
- 2017-05-26 PH PH12017500979A patent/PH12017500979A1/en unknown
- 2017-05-29 CL CL2017001373A patent/CL2017001373A1/es unknown
- 2017-06-02 NI NI201700068A patent/NI201700068A/es unknown
- 2017-06-05 CO CONC2017/0005574A patent/CO2017005574A2/es unknown
-
2019
- 2019-03-19 US US16/357,821 patent/US11224575B2/en active Active
-
2021
- 2021-03-15 US US17/201,811 patent/US11911511B2/en active Active
- 2021-08-13 CY CY20211100730T patent/CY1124504T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017500979A1 (en) | Anticancer compositions | |
| MX2021013965A (es) | Composiciones anticancerigenas. | |
| MX384382B (es) | Composiciones anticancerígenas. | |
| PH12018502334A1 (en) | Anticancer compositions | |
| NZ749218A (en) | Androgen receptor modulator and uses thereof | |
| PH12015501738A1 (en) | Androgen receptor modulators and uses thereof | |
| WO2016172494A3 (en) | Combination of immunotherapy with local chemotherapy for the treatment of malignancies | |
| TH170798A (th) | องค์ประกอบต้านมะเร็ง | |
| Dening | Japan in days of yore; v. 1 | |
| HK1240497A1 (en) | Compositions and methods for treatment of prostate carcinoma |